Use of a VEGF antagonist in treating retinopathy of prematurity

摘要

#$%^&*AU2017204326A120170713.pdf#####1: brInterwovenNRPortblDCCRBR14976607_l docx-26 06/2017 ABSTRACT The present invention relates to the use of a VEGF antagonist in the treatment of retinal neovascular disorders in infants. In particular, the invention provides a method for treating an infant having retinopathy of prematurity (ROP), wherein said method comprises administering 5 to the eye of an infant a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The term "infant" is typically used to refer to young children from birth up to the age of 12 months. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops.